Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 in Neoadjuvant HER2-Positive Breast Cancer
NCT06198751Phase 2Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2102 in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Feb 2024; status: active, not recruiting.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06198751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06198751.